4 Jun 2018
ASCO 2018: Colorectal cancer Q-TWiST with fruquintinib treatment in FRESCO
Upcoming Investor Events
Learn More
THE LANCET :
FRESCO-2, a global Phase III study of fruquintinib in refractory metastatic colorectal cancer
Learn More
THE LANCET HAEMATOLOGY:
Sovleplenib for primary immune thrombocytopenia patients in China
Learn More
European Lung Cancer Congress 2022
Final OS results and subgroup analysis of savolitinib Phase II study in METex14+ NSCLC
Learn More
Latest News
22 Jun 2021HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterationsRead more 18 Jun 2021HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda® in China) for Advanced Pancreatic Neuroendocrine TumorsRead more 18 Jun 2021HUTCHMED Launches Hong Kong Initial Public OfferingRead more
20 May 2021HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific ProgramRead more 17 May 2021Save the date: HUTCHMED to Host Company Update on R&D, Commercial and ASCO Data For Analysts and InvestorsRead more 7 May 2021HUTCHMED to Attend Upcoming Investor ConferencesRead more 4 May 2021Change of Company NameRead more See all
2000
FOUNDED
HCM
NASDAQ &
LONDON AIM
LONDON AIM
13
HKEX
13
IN-HOUSE DISCOVERED
CLINICAL STAGE CANCER
DRUG CANDIDATES
CLINICAL STAGE CANCER
DRUG CANDIDATES
3
APPROVED & MARKETED
PRODUCTS IN CHINA
PRODUCTS IN CHINA
1
APPROVED & MARKETED
PRODUCT IN THE U.S.
PRODUCT IN THE U.S.
~40
CLINICAL TRIALS WORLDWIDE
INCLUDING 13 REGISTRATION STUDIES
INCLUDING 13 REGISTRATION STUDIES
5,000
PERSONNEL ACROSS
THE GROUP
THE GROUP
OUR SCIENCE
Our core research and development philosophy is to take a holistic approach and treat cancer and immunological diseases through multiple modalities and mechanisms. We have taken a science-focused approach to develop highly selective, potent and well-tolerated cancer therapies that are deliberately engineered to improve drug exposure and reduce off-target toxicities.
FOLLOW HUTCHMED ON SOCIAL MEDIA
